drugset
drugset / Trial / NCT05160090

Single Dose Crossover Comparative Bioavailability Study of Bupropion Hcl MR Tablet 300mg

NCT05160090 ↗

Phase 1 Completed 34 enrolled Alembic Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to determine the bioequivalence of 2 different formulations of bupropion after a single oral dose administration under fasting conditions. The secondary objective of this study is to evaluate the safety and tolerability of the Test and Reference formulations in healthy subjects.

Timeline

Start
2020-01-18
Primary completion
2020-02-05
Completion
2020-02-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule 300 mg Oral

Indications

No indication recorded.